ST elevation myocardial infarction risk stratification and prognosis: Difference between revisions
No edit summary |
|||
Line 11: | Line 11: | ||
**The risk score was derived from 14,114 patients enrolled in the [[Intravenous]] nPA for Treatment of Infarcting Myocardium Early II trial (TIME II). | **The risk score was derived from 14,114 patients enrolled in the [[Intravenous]] nPA for Treatment of Infarcting Myocardium Early II trial (TIME II). | ||
**The [[TIMI risk score]] was subsequently validated in an unselected heterogeneous community population through the National Registry of Myocardial Infarction (NRMI) 3 & 4. | **The [[TIMI risk score]] was subsequently validated in an unselected heterogeneous community population through the National Registry of Myocardial Infarction (NRMI) 3 & 4. | ||
The TIMI risk score for TIMI is calculated by adding the numbers assigned to the different criteria shown below. The total possible score is 14.<ref name="pmid11044416">{{cite journal| author=Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA et al.| title=TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. | journal=Circulation | year= 2000 | volume= 102 | issue= 17 | pages= 2031-7 | pmid=11044416 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11044416 }} </ref> | |||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | |||
|- | |||
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 70%" align=center |'''Risk Factor'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''Points''' | |||
|- | |||
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5; width: 70%" align=left colspan=2 |'''''Demographic data and medical history''''' | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Age ≥75 years''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |3 | |||
|- | |||
| style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |''' Age 65–74 years''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left|2 | |||
|- | |||
|style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |'''History of [[diabetes mellitus]] or [[hypertension]] or [[angina]]''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |1 | |||
|- | |||
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5; width: 70%" align=left colspan=2 |'''''Physical examination''''' | |||
|- | |||
|style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |'''Systolic blood pressure <100 ''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |3 | |||
|- | |||
|style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |'''Heart rate >100''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |2 | |||
|- | |||
|style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |'''Killip class II–IV ''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |2 | |||
|- | |||
|style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |'''Weight <67 kg''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |1 | |||
|- | |||
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5; width: 70%" align=left colspan=2 |'''''Evaluation at presentation''''' | |||
|- | |||
|style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |'''Anterior ST elevation or [[left bundle branch block]]''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |1 | |||
|- | |||
|style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |'''Time to therapy >4 hours''' || style="font-size: 100%; padding: 0 5px; background: #B8B8B8" align=left |1 | |||
|} | |||
===Interpretation of TIMI Risk Score for STEMI=== | |||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | |||
|- | |||
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 30%" align=center |'''Score'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''30 Day Mortality (%)'''<ref name="pmid11044416">{{cite journal| author=Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA et al.| title=TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. | journal=Circulation | year= 2000 | volume= 102 | issue= 17 | pages= 2031-7 | pmid=11044416 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11044416 }} </ref> | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''0''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.8% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''1''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1.6% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''2''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |2.2% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''3''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |4.4% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''4''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |7.3% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''5''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |12.4% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''6''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |16.1% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''7''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |23.4% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''8''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |26.8% | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''>8''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |35.9% | |||
|} | |||
*The [[GRACE|Global Registry of Acute Coronary Events (GRACE)]] risk score for [[ACS]]: | *The [[GRACE|Global Registry of Acute Coronary Events (GRACE)]] risk score for [[ACS]]: |
Revision as of 13:55, 7 May 2014
ST Elevation Myocardial Infarction Microchapters |
Differentiating ST elevation myocardial infarction from other Diseases |
Diagnosis |
Treatment |
|
Case Studies |
ST elevation myocardial infarction risk stratification and prognosis On the Web |
FDA on ST elevation myocardial infarction risk stratification and prognosis |
CDC on ST elevation myocardial infarction risk stratification and prognosis |
ST elevation myocardial infarction risk stratification and prognosis in the news |
Blogs on ST elevation myocardial infarction risk stratification and prognosis |
Directions to Hospitals Treating ST elevation myocardial infarction |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Two main risk-stratification scores are used when assessing a patient with ST elevation MI and acute coronary syndromes; the TIMI Risk Score (for STEMI), and the GRACE risk score (for acute coronary syndrome.
Risk Stratification in a Patient with ST Elevation MI
- The Thrombolysis in Myocardial Infarction (TIMI) risk score for STEMI:
- The TIMI risk score for STEMI was created from simple arithmetic sum of independent predictors of mortality weighted according to the adjusted odds ratios from logistic regression analysis.
- The risk score was derived from 14,114 patients enrolled in the Intravenous nPA for Treatment of Infarcting Myocardium Early II trial (TIME II).
- The TIMI risk score was subsequently validated in an unselected heterogeneous community population through the National Registry of Myocardial Infarction (NRMI) 3 & 4.
The TIMI risk score for TIMI is calculated by adding the numbers assigned to the different criteria shown below. The total possible score is 14.[1]
Risk Factor | Points |
Demographic data and medical history | |
Age ≥75 years | 3 |
Age 65–74 years | 2 |
History of diabetes mellitus or hypertension or angina | 1 |
Physical examination | |
Systolic blood pressure <100 | 3 |
Heart rate >100 | 2 |
Killip class II–IV | 2 |
Weight <67 kg | 1 |
Evaluation at presentation | |
Anterior ST elevation or left bundle branch block | 1 |
Time to therapy >4 hours | 1 |
Interpretation of TIMI Risk Score for STEMI
Score | 30 Day Mortality (%)[1] |
0 | 0.8% |
1 | 1.6% |
2 | 2.2% |
3 | 4.4% |
4 | 7.3% |
5 | 12.4% |
6 | 16.1% |
7 | 23.4% |
8 | 26.8% |
>8 | 35.9% |
- The Global Registry of Acute Coronary Events (GRACE) risk score for ACS:
- The GRACE risk score was created from a multivariable logistic regression model using ACS patients enrolled in the GRACE registry (N=11389).
- The GRACE risk score was validated using subsequent cohort of patients enrolled in GRACE (n=3972) and the Global Use of Strategies to Open Occluded Coronary Arteries IIb (GUSTO-IIb) trial (n=12142).
- The AHA/ACCA Guidelines for Unstable Angina/Non -ST-Elevation Myocardial Infarction provide guidelines for risk stratification for ACS.
References
- ↑ 1.0 1.1 Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA; et al. (2000). "TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy". Circulation. 102 (17): 2031–7. PMID 11044416.